Please assess the completion status of the following clinical trial:

Trial Title: Phase I Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of DA-7218 in Healthy Male Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male Korean 19-45 years~* Body weight:55-90kg, BMI:18.0-27.0~Exclusion Criteria:~* Present condition or history of any clinically significant disease~* Clinical evidence or history of GI disease or history of GI surgery~* History of hypersensitivities, including drug allergies~* AST (SGOT) or ALT (SGPT) \> 1.5 times the upper normal limit~* Systolic blood pressure : \<100 mmHg or \>160 mmHg~* Diastolic blood pressure : \<60 mmHg or \>100 mmHg~* Drug abuse within 2 months, or a positive reaction to an abusive drug or cotinine~* Taken any ETC or herbal supplement within 2 weeks or any OTC or vitamin supplement within 1 week~* Participation in and administration of IP of another clinical trial within 2 months~* Donation of whole blood within 2 months, or blood components within 1 month, or receipt of blood transfusion within 1 month~* Consumption of more than 21 units of alcohol/week or inability to abstain from drinking during the study period~* Smoking within 3 months~* Taking caffeine- or grapefruit-containing products within 3 days~* Plan to be pregnant, or not to use an appropriate method of contraception

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- [Group 1] DA-7218 (Type: EXPERIMENTAL): 200mg, By mouth or orally (PO) \& intravenous(IV) administration
- [Group 1] Placebo (Type: PLACEBO_COMPARATOR): Placebo, By mouth or orally (PO) \& intravenous(IV) administration
- [Group 2] DA-7218 (Type: EXPERIMENTAL): 400mg, By mouth or orally (PO) administration
- [Group 2] Placebo (Type: PLACEBO_COMPARATOR): Placebo, By mouth or orally (PO) administration
- [Group 3] DA-7218 (Type: EXPERIMENTAL): 600mg, By mouth or orally (PO) administration
- [Group 3] Placebo (Type: PLACEBO_COMPARATOR): Placebo, By mouth or orally (PO) administration

Based on this trial design, predict the completion outcome and termination type (if applicable).